Anzeige
Mehr »
Login
Freitag, 26.04.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Wie die Revolution der sauberen Energie eine solide Investitionsmöglichkeit bieten könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
318 Leser
Artikel bewerten:
(1)

Hallura Announces the Appointment of Paul Navarre to Its Board of Directors

YOKNEAM, Israel, July 1, 2020 /PRNewswire/ -- Hallura Ltd., an Israeli aesthetic medical company developing the next generation of Hyaluronic Acid (HA) Dermal Fillers, today announced that it has appointed Mr. Paul Navarre to serve as an independent director of Hallura's Board of Directors.

"We are excited to welcome Mr. Paul Navarre as he brings a wealth of knowledge and experience to Hallura's board," said Dr. Shimon Eckhouse, co-founder and Chairman of Hallura. "His exceptional track record made Paul a respected and well-known executive in the industry. Paul shares our vision on how Hallura's technology is disruptive and can transform the industry. Paul's unique insights will help guide the vision and strategic opportunities of Hallura."

Mr. Paul Navarre commented "I am very excited to join the Board of Directors. Hallura is at the forefront of the technology that will allow to access the next generation of aesthetic treatments. The great progresses Hallura did in the last two years make it an exciting time to join the company and I look forward to bringing my experience to the Board."

Paul Navarre has more than 25 years' experience in the pharmaceuticals and consumer goods industries. He was Chief Executive Officer of Ferring Holding Inc (US) between 2017 and 2020, managing activities including commercial operations, clinical development and manufacturing. Previously, as President of Allergan International, he managed a $3 billion specialty care business covering dermatology, ophthalmology, urology and neurosciences. During 10 years at Allergan, Mr. Navarre built a strong track record in the aesthetic medical market, delivering solid business results and developing multiple successful organizations. Before joining Allergan, Mr. Navarre spent 15 years at Procter & Gamble, starting in consumer goods before moving to the company's pharmaceuticals division.

About Hallura Ltd.

Hallura Ltd. brings a disruptive HA technology to the fast growing aesthetic injectables market using proprietary HA crosslinking technology, not involving BDDE. Hallura's HA dermal fillers answer the growing demand for better, safer fillers with natural and soft aesthetic results.

Founded in November 2017 by Dr. Stéphane Meunier, Mrs. Alona Gellerman, Dr. Per Hedén and Dr. Shimon Eckhouse and with its headquarters, R&D, and manufacturing in Yokneam Israel. Hallura is a portfolio company of Alon Medtech Ventures owned by Dr. Shimon Eckhouse.

Contact person: Dr. Stephane Meunier, Chief Executive Officer at Hallura; stephane@hallura.com

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2020 PR Newswire
Diesen Artikel auf Deutsch lesen
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.